ABCL logo

AbCellera Biologics Inc. (ABCL) Cash From Financing

Annual CFF:

$12.77M+$2.41M(+23.30%)
December 31, 2024

Summary

  • As of today, ABCL annual cash from financing is $12.77 million, with the most recent change of +$2.41 million (+23.30%) on December 31, 2024.
  • During the last 3 years, ABCL annual cash from financing has risen by +$16.66 million (+428.59%).
  • ABCL annual cash from financing is now -98.13% below its all-time high of $683.65 million, reached on December 31, 2020.

Performance

ABCL Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherABCLcash flow metrics

Quarterly CFF:

$7.48M+$10.80M(+324.68%)
September 30, 2025

Summary

  • As of today, ABCL quarterly cash from financing is $7.48 million, with the most recent change of +$10.80 million (+324.68%) on September 30, 2025.
  • Over the past year, ABCL quarterly cash from financing has increased by +$4.33 million (+137.33%).
  • ABCL quarterly cash from financing is now -98.81% below its all-time high of $629.01 million, reached on December 31, 2020.

Performance

ABCL Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherABCLcash flow metrics

TTM CFF:

$14.03M+$4.33M(+44.56%)
September 30, 2025

Summary

  • As of today, ABCL TTM cash from financing is $14.03 million, with the most recent change of +$4.33 million (+44.56%) on September 30, 2025.
  • Over the past year, ABCL TTM cash from financing has increased by +$1.80 million (+14.69%).
  • ABCL TTM cash from financing is now -98.01% below its all-time high of $705.00 million, reached on December 31, 2020.

Performance

ABCL TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherABCLcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

ABCL Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+23.3%+137.3%+14.7%
3Y3 Years+428.6%+10000.0%+10000.0%
5Y5 Years+6448.2%+161.8%-81.5%

ABCL Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+428.6%at high+324.7%-10.9%+999.0%
5Y5-Year-98.1%+428.6%-98.8%+161.8%-98.0%+357.4%
All-TimeAll-Time-98.1%+428.6%-98.8%+161.8%-98.0%+357.4%

ABCL Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2025
-
$7.48M(+324.7%)
$14.03M(+44.6%)
Jun 2025
-
-$3.33M(-155.7%)
$9.71M(-38.0%)
Mar 2025
-
$5.97M(+52.5%)
$15.65M(+25.1%)
Dec 2024
$12.77M(+23.3%)
$3.92M(+24.3%)
$12.51M(+2.2%)
Sep 2024
-
$3.15M(+20.6%)
$12.24M(-22.3%)
Jun 2024
-
$2.61M(-7.7%)
$15.74M(+16.2%)
Mar 2024
-
$2.83M(-22.3%)
$13.55M(+32.0%)
Dec 2023
$10.36M(+736.1%)
$3.64M(-45.3%)
$10.26M(+46.6%)
Sep 2023
-
$6.66M(+1489.4%)
$7.00M(+1900.5%)
Jun 2023
-
$418.90K(+191.5%)
$349.90K(-68.5%)
Mar 2023
-
-$458.00K(-220.2%)
$1.11M(+171.2%)
Dec 2022
-$1.63M
$380.90K(+4602.5%)
-$1.56M(-1290.1%)
DateAnnualQuarterlyTTM
Sep 2022
-
$8100.00(-99.3%)
-$112.30K(-112.4%)
Jun 2022
-
$1.18M(+137.7%)
$905.90K(+116.6%)
Mar 2022
-
-$3.13M(-271.1%)
-$5.45M(-41.1%)
Dec 2021
-$3.89M(-100.6%)
$1.83M(+78.3%)
-$3.86M(-100.6%)
Sep 2021
-
$1.03M(+119.8%)
$623.31M(+2.1%)
Jun 2021
-
-$5.18M(-235.6%)
$610.19M(-0.9%)
Mar 2021
-
-$1.54M(-100.2%)
$615.72M(-12.7%)
Dec 2020
$683.65M(>+9900.0%)
$629.01M(+5301.7%)
$705.00M(+827.7%)
Sep 2020
-
-$12.09M(-3594.9%)
$75.99M(-13.7%)
Jun 2020
-
$346.00K(-99.6%)
$88.08M(+0.4%)
Mar 2020
-
$87.74M
$87.74M
Dec 2019
$195.00K(-98.4%)
-
-
Dec 2018
$12.19M
-
-

FAQ

  • What is AbCellera Biologics Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for AbCellera Biologics Inc.?
  • What is AbCellera Biologics Inc. annual cash from financing year-on-year change?
  • What is AbCellera Biologics Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for AbCellera Biologics Inc.?
  • What is AbCellera Biologics Inc. quarterly cash from financing year-on-year change?
  • What is AbCellera Biologics Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for AbCellera Biologics Inc.?
  • What is AbCellera Biologics Inc. TTM cash from financing year-on-year change?

What is AbCellera Biologics Inc. annual cash from financing?

The current annual cash from financing of ABCL is $12.77M

What is the all-time high annual cash from financing for AbCellera Biologics Inc.?

AbCellera Biologics Inc. all-time high annual cash from financing is $683.65M

What is AbCellera Biologics Inc. annual cash from financing year-on-year change?

Over the past year, ABCL annual cash from financing has changed by +$2.41M (+23.30%)

What is AbCellera Biologics Inc. quarterly cash from financing?

The current quarterly cash from financing of ABCL is $7.48M

What is the all-time high quarterly cash from financing for AbCellera Biologics Inc.?

AbCellera Biologics Inc. all-time high quarterly cash from financing is $629.01M

What is AbCellera Biologics Inc. quarterly cash from financing year-on-year change?

Over the past year, ABCL quarterly cash from financing has changed by +$4.33M (+137.33%)

What is AbCellera Biologics Inc. TTM cash from financing?

The current TTM cash from financing of ABCL is $14.03M

What is the all-time high TTM cash from financing for AbCellera Biologics Inc.?

AbCellera Biologics Inc. all-time high TTM cash from financing is $705.00M

What is AbCellera Biologics Inc. TTM cash from financing year-on-year change?

Over the past year, ABCL TTM cash from financing has changed by +$1.80M (+14.69%)
On this page